NEOGENOMICS INC (NEO) Fundamental Analysis & Valuation

NASDAQ:NEO • US64049M2098

Current stock price

8.27 USD
+0.03 (+0.36%)
At close:
8.33 USD
+0.06 (+0.73%)
Pre-Market:

This NEO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. NEO Profitability Analysis

1.1 Basic Checks

  • NEO had positive earnings in the past year.
  • NEO had a positive operating cash flow in the past year.
  • NEO had negative earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: NEO reported negative operating cash flow in multiple years.
NEO Yearly Net Income VS EBIT VS OCF VS FCFNEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

  • NEO has a Return On Assets of -7.94%. This is in the lower half of the industry: NEO underperforms 70.30% of its industry peers.
  • NEO has a worse Return On Equity (-12.91%) than 61.39% of its industry peers.
Industry RankSector Rank
ROA -7.94%
ROE -12.91%
ROIC N/A
ROA(3y)-5.99%
ROA(5y)-5.34%
ROE(3y)-10.33%
ROE(5y)-9.24%
ROIC(3y)N/A
ROIC(5y)N/A
NEO Yearly ROA, ROE, ROICNEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15

1.3 Margins

  • NEO has a Gross Margin of 43.21%. This is in the better half of the industry: NEO outperforms 72.28% of its industry peers.
  • In the last couple of years the Gross Margin of NEO has remained more or less at the same level.
  • NEO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.44%
GM growth 5Y0.65%
NEO Yearly Profit, Operating, Gross MarginsNEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. NEO Health Analysis

2.1 Basic Checks

  • NEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NEO has been increased compared to 1 year ago.
  • NEO has more shares outstanding than it did 5 years ago.
  • NEO has a better debt/assets ratio than last year.
NEO Yearly Shares OutstandingNEO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
NEO Yearly Total Debt VS Total AssetsNEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of 1.36, we must say that NEO is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of NEO (1.36) is worse than 60.40% of its industry peers.
  • NEO has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
  • NEO's Debt to Equity ratio of 0.41 is fine compared to the rest of the industry. NEO outperforms 64.36% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z 1.36
ROIC/WACCN/A
WACC6.98%
NEO Yearly LT Debt VS Equity VS FCFNEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 4.26 indicates that NEO has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 4.26, NEO belongs to the best of the industry, outperforming 91.09% of the companies in the same industry.
  • A Quick Ratio of 3.94 indicates that NEO has no problem at all paying its short term obligations.
  • NEO has a better Quick ratio (3.94) than 90.10% of its industry peers.
Industry RankSector Rank
Current Ratio 4.26
Quick Ratio 3.94
NEO Yearly Current Assets VS Current LiabilitesNEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. NEO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.00% over the past year.
  • NEO shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -3.04% yearly.
  • The Revenue has grown by 10.11% in the past year. This is quite good.
  • The Revenue has been growing by 10.35% on average over the past years. This is quite good.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5Y-3.04%
EPS Q2Q%50%
Revenue 1Y (TTM)10.11%
Revenue growth 3Y12.58%
Revenue growth 5Y10.35%
Sales Q2Q%10.56%

3.2 Future

  • Based on estimates for the next years, NEO will show a very strong growth in Earnings Per Share. The EPS will grow by 46.80% on average per year.
  • Based on estimates for the next years, NEO will show a quite strong growth in Revenue. The Revenue will grow by 8.82% on average per year.
EPS Next Y39.26%
EPS Next 2Y62.68%
EPS Next 3Y55.16%
EPS Next 5Y46.8%
Revenue Next Year9.85%
Revenue Next 2Y9.79%
Revenue Next 3Y9.56%
Revenue Next 5Y8.82%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
NEO Yearly Revenue VS EstimatesNEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
NEO Yearly EPS VS EstimatesNEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5

More info and screens

Find the best growth stocksShow best growing peers

2

4. NEO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 68.92, which means the current valuation is very expensive for NEO.
  • NEO's Price/Earnings ratio is in line with the industry average.
  • When comparing the Price/Earnings ratio of NEO to the average of the S&P500 Index (26.11), we can say NEO is valued expensively.
  • The Price/Forward Earnings ratio is 49.49, which means the current valuation is very expensive for NEO.
  • NEO's Price/Forward Earnings is on the same level as the industry average.
  • NEO is valuated expensively when we compare the Price/Forward Earnings ratio to 24.12, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 68.92
Fwd PE 49.49
NEO Price Earnings VS Forward Price EarningsNEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEO Per share dataNEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • NEO's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • NEO's earnings are expected to grow with 55.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.76
PEG (5Y)N/A
EPS Next 2Y62.68%
EPS Next 3Y55.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NEO Dividend Analysis

5.1 Amount

  • No dividends for NEO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEO Fundamentals: All Metrics, Ratios and Statistics

NEOGENOMICS INC

NASDAQ:NEO (3/17/2026, 8:00:02 PM)

Premarket: 8.33 +0.06 (+0.73%)

8.27

+0.03 (+0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-17
Earnings (Next)04-27
Inst Owners107.44%
Inst Owner Change0.25%
Ins Owners1.16%
Ins Owner Change1.61%
Market Cap1.07B
Revenue(TTM)727.33M
Net Income(TTM)-108.03M
Analysts72.22
Price Target14.11 (70.62%)
Short Float %6.61%
Short Ratio4.33
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.26%
Min EPS beat(2)40.97%
Max EPS beat(2)53.54%
EPS beat(4)4
Avg EPS beat(4)56.53%
Min EPS beat(4)31.6%
Max EPS beat(4)100%
EPS beat(8)8
Avg EPS beat(8)186.32%
EPS beat(12)12
Avg EPS beat(12)158.94%
EPS beat(16)16
Avg EPS beat(16)128.09%
Revenue beat(2)2
Avg Revenue beat(2)0.65%
Min Revenue beat(2)0.13%
Max Revenue beat(2)1.18%
Revenue beat(4)2
Avg Revenue beat(4)-0.78%
Min Revenue beat(4)-2.68%
Max Revenue beat(4)1.18%
Revenue beat(8)4
Avg Revenue beat(8)-0.18%
Revenue beat(12)8
Avg Revenue beat(12)1.59%
Revenue beat(16)11
Avg Revenue beat(16)1.85%
PT rev (1m)2.47%
PT rev (3m)12.16%
EPS NQ rev (1m)-39.86%
EPS NQ rev (3m)-12.5%
EPS NY rev (1m)3.04%
EPS NY rev (3m)-0.24%
Revenue NQ rev (1m)-1.54%
Revenue NQ rev (3m)-1.72%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)-0.04%
Valuation
Industry RankSector Rank
PE 68.92
Fwd PE 49.49
P/S 1.48
P/FCF N/A
P/OCF 205.26
P/B 1.28
P/tB 41.79
EV/EBITDA N/A
EPS(TTM)0.12
EY1.45%
EPS(NY)0.17
Fwd EY2.02%
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)0.04
OCFY0.49%
SpS5.6
BVpS6.44
TBVpS0.2
PEG (NY)1.76
PEG (5Y)N/A
Graham Number4.17
Profitability
Industry RankSector Rank
ROA -7.94%
ROE -12.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.21%
FCFM N/A
ROA(3y)-5.99%
ROA(5y)-5.34%
ROE(3y)-10.33%
ROE(5y)-9.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.44%
GM growth 5Y0.65%
F-Score4
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.82%
Cap/Sales 3.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.26
Quick Ratio 3.94
Altman-Z 1.36
F-Score4
WACC6.98%
ROIC/WACCN/A
Cap/Depr(3y)45.34%
Cap/Depr(5y)60.15%
Cap/Sales(3y)4.93%
Cap/Sales(5y)6.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5Y-3.04%
EPS Q2Q%50%
EPS Next Y39.26%
EPS Next 2Y62.68%
EPS Next 3Y55.16%
EPS Next 5Y46.8%
Revenue 1Y (TTM)10.11%
Revenue growth 3Y12.58%
Revenue growth 5Y10.35%
Sales Q2Q%10.56%
Revenue Next Year9.85%
Revenue Next 2Y9.79%
Revenue Next 3Y9.56%
Revenue Next 5Y8.82%
EBIT growth 1Y-3.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year150.01%
EBIT Next 3Y42.58%
EBIT Next 5Y34.35%
FCF growth 1Y36.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.53%
OCF growth 3YN/A
OCF growth 5Y29.07%

NEOGENOMICS INC / NEO Fundamental Analysis FAQ

What is the fundamental rating for NEO stock?

ChartMill assigns a fundamental rating of 4 / 10 to NEO.


What is the valuation status for NEO stock?

ChartMill assigns a valuation rating of 2 / 10 to NEOGENOMICS INC (NEO). This can be considered as Overvalued.


How profitable is NEOGENOMICS INC (NEO) stock?

NEOGENOMICS INC (NEO) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for NEO stock?

The Earnings per Share (EPS) of NEOGENOMICS INC (NEO) is expected to grow by 39.26% in the next year.